Sign in
PBIGF Stock Price, Chart, Stats & News
Paradigm Biopharmaceuticals Limited
Save
Paradigm Biopharmaceuticals Limited (PBIGF) does not currently pay a dividend.
59.92M
Market cap
–
Current P/E
–
Forward P/E
PBIGF chart
1M
3M
1Y
5Y
Loading chart...
About
Health care
Sector
Biotechnology
Industry
Melbourne, Australia-based Paradigm Biopharmaceuticals Limited operates as a drug repurposing company, focusing on the discovery and development of therapeutic products for human application. The company's core offering is an injectable formulation of pentosan polysulfate sodium (PPS), which is being developed to address various medical conditions including osteoarthritis, mucopolysaccharidosis, Ross River virus, Chikungunya virus, and acute respiratory distress syndrome. The company was established in 2014.
Similar securities
Based on sector and market capitalization
Report issue